Induction of mitochondrial changes in myeloma cells by imexon

Blood

Volumn 97, Issue 11, 2001, Pages 3544-3551

  Dvorakova, Katerina ^a   Waltmire, Caroline N ^a   Payne, Claire M ^a   Tome, Margaret E ^a   Briehl, Margaret M ^a   Dorr, Robert T ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; IMEXON; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE; MEMBRANE POTENTIAL; MITOCHONDRION; MYELOMA CELL; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0035383778     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3544     Document Type: Article

References (50)

1. Dorr RT, Liddil JD, Klein MK, Hersh EM. Preclinical pharmacokinetics and antitumor activity of imexon. Invest New Drugs. 1995;13:113-116.
2. Micksche M, Kokoschka EM, Sagaster P, Bicker U. Phase I study for a new immunomodulating drug, BM 006 00002, in man. In: Chirigos MA, ed. Immune Modulation and Control of Neoplasia by Adjuvant Therapy. New York: Raven Press; 1978: 4003-413.
3. Salmon SE, Hersh EM. Sensitivity of multiple myeloma to imexon in the human tumor cloning assay [see comments]. J Natl Cancer Inst. 1994;86: 228-2300.
4. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol. 2000;60:749-758.
5. Shi X. Pharmacology of imexon and related analogs. Department of Pharmacology and Toxicology. Tucson: University of Arizona; 1995:62.
6. Lemasters JJ, Qian T, Bradham CA, et al. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J Bioenerg Biomembr. 1999;31:305-319.
7. Chernyak BV. Redox regulation of the mitochondrial permeability transition pore. Biosci Rep. 1997;17:293-302.
8. Skulachev VP. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Lett. 1996;397:7-10.
9. Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta. 1998;1366:139-149.
10. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
11. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochonddal death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619-642.
12. Hirsch T, Marzo I, Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep. 1997;17:67-76.
13. Merad-Boudia M, Nicole A, Santiard-Baron D, Sallie C, Ceballos-Picot I. Mitochonddal impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem Pharmacol. 1998;56:645-655.
14. Sato N, Iwata S, Nakamura K, Hod T, Mod K, Yodoi J. Thiol-mediated redox regulation of apoptosis: possible roles of cellular thiols other than glutathione in T cell apoptosis. J Immunol. 1995;154: 3194-3203.
15. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93:268-277.
16. Edelson PJ, Cohn ZA. Purification and cultivation of monocytes and macrophages. In Bloom BR, David JR, eds. In vitro Methods in Cell-Mediated and Tumor Immunity. New York: Academic Press; 1976:333-340.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
18. van de Water B, Zoeteweij JP, de Bont HJ, Nagelkerke JF. Inhibition of succinate:ubiquinone reductase and decrease of ubiquinol in nephrotoxic cysteine S-conjugate-induced oxidative cell injury. Mol Pharmacol. 1995;48:928-937.
19. Payne CM, Bjore CG Jr, Schultz DA. Change in the frequency of apoptosis after low- and high-dose X-irradiation of human lymphocytes. J Leukoc Biol. 1992;52:433-440.
20. Macho A, Decaudin D, Castedo M, et al. Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis [see comments]. Cytometry. 1996;25:333-340.
21. Poot M, Pierce RH. Detection of changes in mitochondrial function during apoptosis by simultaneous staining with multiple fluorescent dyes and correlated multiparameter flow cytometry. Cytometry. 1999;35:311-317.
22. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7[preim]-dichlorofluorescin. J Leukoc Biol. 1990;47:440-448.
23. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria [see comments]. Cell. 1997;91: 627-637.
24. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem. 1987; 163:279]. Anal Biochem. 1985;150:76-85.
25. Laemmli UK, Beguin F, Gujer-Kellenberger G. A factor preventing the major head protein of bacteriophage T4 from random aggregation. J Mol Biol. 1970;47:69-85.
26. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997;94:514-519.
27. Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JF. An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol. 1975;116:129-138.
28. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu. 1982;17:229-259.
29. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis [see comments]. Immunol Today. 1994;15:7-10.
30. Powis G, Briehl M, Oblong J. Redox signalling and the control of cell growth and death. Pharmacol Ther. 1995;68:149-173.
31. Richter C, Gogvadze V, Laffranchi R, et al. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta. 1995;1271:67-74.
32. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci. 1996; 21:83-86.
33. Hirsch T, Marchetti P, Susin SA, et al. The apoptosis-necrosis paradox: apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene. 1997;15:1573-1581.
34. Scaduto RC Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J. 1999;76: 469-477.
35. Micksche M, Kokoschka EM, Kokren O, Sagaster P, Bicker U. Immune stimulation in cancer patients by a new synthetic compound: BM 06 002. Osterr Kneipp Mag. 1977;4:29-32.
36. Mead JR, Burger RA, Morrey JD, Warren RP, Okleberry KM, Sidwell RW. Effect of immunomodulators in the hu-PBL-SCID mouse model. Biotechnol Ther. 1993;4:133-143.
37. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro [see comments]. J Natl Cancer Inst. 1992; 84;1238-1244.
38. Hersh EM, Grogan TM, Funk CY, Taylor CW. Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy. J Immunother. 1993;13:77-83.
39. Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol. 1990;30:603-631.
40. Payne CM, Bernstein C, Bernstein H. Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Leuk Lymphoma. 1995;19:43-93.
41. Cai J, Jones DP. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. J Biol Chem. 1998;273:11401-11404.
42. Watson RW, Rotstein OD, Nathens AB, Dackiw AP, Marshall JC. Thiol-mediated redox regulation of neutrophil apoptosis. Surgery. 1996;120:150-157 (discussion 157-158).
43. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene. 1997;15:1461-1470.
44. Crowley CL, Payne CM, Bernstein H, Bernstein C, Roe D. The NAD+ precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate. Cell Death Differ. 2000;7:314-326.
45. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today. 1997;18:44-51.
46. Karbowski M, Kurono C, Wozniak M, et al. Free radical-induced megamitochondria formation and apoptosis. Free Radic Biol Med. 1999;26:396-409.
47. Dansky-Ullmann C, Shaw GL, Collins G, Taub D. Selective blocking of constitutive NFkB activity in human multiple myeloma cells induces growth inhibition and increased apoptosis. Proceedings of the 91st annual meeting American Association for Cancer Research. San Francisco, April 2000; 41:761.
48. Hamburger AW, Kim MB, Salmon SE. The nature of cells generating human myeloma colonies in vitro. J Cell Physiol. 1979;98:371-376.
49. Park CH. Vitamin C in leukemia and preleukemia cell growth. Prog Clin Biol Res. 1988;259:321-330.
50. Oberley LW, Oberley TD. Role of antioxidant enzymes in cell immortalization and transformation. Mol Cell Biochem. 1988;84:147-153.